Details for Patent: 11,793,819
✉ Email this page to a colleague
Which drugs does patent 11,793,819 protect, and when does it expire?
Patent 11,793,819 protects BIJUVA and is included in one NDA.
This patent has one hundred and sixty-one patent family members in twenty-one countries.
Drugs Protected by US Patent 11,793,819
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | BIJUVA | estradiol; progesterone | CAPSULE;ORAL | 210132-002 | Dec 28, 2021 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS | ⤷ Subscribe | ||||
| Mayne Pharma | BIJUVA | estradiol; progesterone | CAPSULE;ORAL | 210132-001 | Oct 28, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,793,819
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2782584 | ⤷ Subscribe | 301153 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2782584 | ⤷ Subscribe | 2021C/558 | Belgium | ⤷ Subscribe |
| European Patent Office | 2782584 | ⤷ Subscribe | 122021000080 | Germany | ⤷ Subscribe |
| European Patent Office | 2782584 | ⤷ Subscribe | LUC00245 | Luxembourg | ⤷ Subscribe |
| European Patent Office | 2782584 | ⤷ Subscribe | 132021000000197 | Italy | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
